Definitive local therapy for T4 prostate cancer associated with improved local control and survival

Abstract

ObjectivesTo evaluate patients with clinical (c)T4 prostate cancer (PCa), which represent both a heterogenous and understudied population, who often present with locally advanced disease and obstructive symptoms causing significant morbidity and mortality. We analysed whether receiving definitive local therapy influenced symptomatic and oncological outcomes.MethodsRetrospective analysis of 154 patients with cT4 PCa treated at a single institution in 1996–2020. Systemic therapy with or without local treatment (surgery, radiotherapy [RT], or both). Uni‐ and multivariate analyses of associations between clinicopathological features (including obstructive symptoms) and receipt of local therapy on overall survival (OS) and disease control were done with Cox regression.ResultsThe median follow‐up time was 5.9 years. Most patients had adenocarcinoma (88%), Gleason score 9–10 (77%), and median baseline prostate‐specific antigen (PSA) of 20 ng/mL; most (54%) had metastatic cT4N0–1M1 disease; 24% regionally advanced cT4N1M0, and 22% localised cT4N0M0. Local therapies were RT (n = 44), surgery (n = 28), or both (n = nine). Local therapy was associated with improved OS (hazard ratio [HR] 0.3, P < 0.001), longer freedom from local recurrence (HR 0.39, P = 0.002), less local progression (HR 0.41, P = 0.02), fewer obstructive symptoms with progression (HR 0.31, P = 0.01), and less death from local disease (HR 0.25, P = 0.002). On multivariate, local therapy was associated with improved survival (HR 0.58, P = 0.02), and metastatic disease (HR 2.93, P < 0.001) or high‐risk pathology (HR 2.05, P = 0.03) was associated with worse survival.ConclusionDefinitive local therapy for cT4 PCa was associated with improved symptomatic outcomes and survival even among men with metastatic disease. Pending prospective evaluation, these findings support definitive treatment with local therapy for cT4 disease in select cases.